827 related articles for article (PubMed ID: 18243663)
1. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.
Tandon R; Belmaker RH; Gattaz WF; Lopez-Ibor JJ; Okasha A; Singh B; Stein DJ; Olie JP; Fleischhacker WW; Moeller HJ;
Schizophr Res; 2008 Mar; 100(1-3):20-38. PubMed ID: 18243663
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.
Chakos M; Lieberman J; Hoffman E; Bradford D; Sheitman B
Am J Psychiatry; 2001 Apr; 158(4):518-26. PubMed ID: 11282684
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotics in the treatment of schizophrenia: an overview.
Tandon R
J Clin Psychiatry; 2011; 72 Suppl 1():4-8. PubMed ID: 22217436
[TBL] [Abstract][Full Text] [Related]
4. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study.
Tenback DE; van Harten PN; Slooff CJ; Belger MA; van Os J;
J Clin Psychiatry; 2005 Sep; 66(9):1130-3. PubMed ID: 16187770
[TBL] [Abstract][Full Text] [Related]
5. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Stip E; Tourjman V
Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic treatment of schizophrenia: an update.
Bruijnzeel D; Suryadevara U; Tandon R
Asian J Psychiatr; 2014 Oct; 11():3-7. PubMed ID: 25216917
[TBL] [Abstract][Full Text] [Related]
7. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic safety and efficacy concerns.
Meyer JM
J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
[TBL] [Abstract][Full Text] [Related]
9. Second generation antipsychotics for schizophrenia.
Feltus MS; Gardner DM
Can J Clin Pharmacol; 1999; 6(4):187-95. PubMed ID: 10601752
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment.
Tandon R; Fleischhacker WW
Schizophr Res; 2005 Nov; 79(2-3):145-55. PubMed ID: 16139989
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Rosenheck RA; Leslie DL; Sindelar J; Miller EA; Lin H; Stroup TS; McEvoy J; Davis SM; Keefe RS; Swartz M; Perkins DO; Hsiao JK; Lieberman J;
Am J Psychiatry; 2006 Dec; 163(12):2080-9. PubMed ID: 17151158
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis.
Hartling L; Abou-Setta AM; Dursun S; Mousavi SS; Pasichnyk D; Newton AS
Ann Intern Med; 2012 Oct; 157(7):498-511. PubMed ID: 22893011
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of newer generation antipsychotics in the treatment of schizophrenia.
Tandon R; Jibson MD
Psychoneuroendocrinology; 2003 Jan; 28 Suppl 1():9-26. PubMed ID: 12504069
[TBL] [Abstract][Full Text] [Related]
14. [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia].
Samalin L; Ben Gharbia M; Garnier M; Llorca PM
Encephale; 2014 Dec; 40(6):507-17. PubMed ID: 25453735
[TBL] [Abstract][Full Text] [Related]
15. Lurasidone in the treatment of schizophrenia: a critical evaluation.
Bruijnzeel D; Yazdanpanah M; Suryadevara U; Tandon R
Expert Opin Pharmacother; 2015; 16(10):1559-65. PubMed ID: 26111577
[TBL] [Abstract][Full Text] [Related]
16. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia.
Montgomery JH; Byerly M; Carmody T; Li B; Miller DR; Varghese F; Holland R
Control Clin Trials; 2004 Dec; 25(6):598-612. PubMed ID: 15588746
[TBL] [Abstract][Full Text] [Related]
17. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
Wheeler AJ
Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
[TBL] [Abstract][Full Text] [Related]
19. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.
Volavka J; Citrome L
Expert Opin Pharmacother; 2009 Aug; 10(12):1917-28. PubMed ID: 19558339
[TBL] [Abstract][Full Text] [Related]
20. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
Bishara D; Taylor D
Drugs; 2008; 68(16):2269-92. PubMed ID: 18973393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
